Keros Therapeutics, a Phase 1 biotech developing therapies for blood and musculoskeletal disorders, raised $96 million by offering 6.0 million shares at $16, the high end of the range of $14 to $16. Keros upsized its offering by 1.0 million shares (20%).
Keros Therapeutics plans to list on the Nasdaq under the symbol KROS. Jefferies, SVB Leerink and Piper Sandler acted as lead managers on the deal.
